ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08575
-0,03%
Bitcoin
70.105,40
-1,88%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) News

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:AIM
DatumZeitQuelleÜberschriftSymbolFirma
20/05/202415h15GlobeNewswire Inc.AIM ImmunoTech to Participate in Two Upcoming Investor ConferencesAMEX:AIMAIM ImmunoTech Inc
16/05/202413h30GlobeNewswire Inc.AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
15/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:AIMAIM ImmunoTech Inc
09/05/202414h50GlobeNewswire Inc.AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
07/05/202414h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
07/05/202414h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
06/05/202414h30GlobeNewswire Inc.AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®AMEX:AIMAIM ImmunoTech Inc
29/04/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
25/04/202414h45GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
18/04/202414h45GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
15/04/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsAMEX:AIMAIM ImmunoTech Inc
11/04/202417h00GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
10/04/202414h21GlobeNewswire Inc.AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerAMEX:AIMAIM ImmunoTech Inc
02/04/202413h30GlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
28/03/202413h05GlobeNewswire Inc.AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceAMEX:AIMAIM ImmunoTech Inc
26/03/202414h05GlobeNewswire Inc.AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
25/03/202414h05GlobeNewswire Inc.AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchAMEX:AIMAIM ImmunoTech Inc
22/03/202413h55GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
20/03/202414h25GlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
15/03/202413h45GlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityAMEX:AIMAIM ImmunoTech Inc
07/03/202414h45GlobeNewswire Inc.AIM ImmunoTech Announces Launch of CEO Corner PlatformAMEX:AIMAIM ImmunoTech Inc
29/02/202414h45GlobeNewswire Inc.AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateAMEX:AIMAIM ImmunoTech Inc
21/02/202416h37Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
20/02/202422h34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:AIMAIM ImmunoTech Inc
20/02/202422h31Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
14/02/202414h55GlobeNewswire Inc.AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
09/02/202421h47Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
08/02/202414h50GlobeNewswire Inc.AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAMEX:AIMAIM ImmunoTech Inc
25/01/202423h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
24/01/202415h10GlobeNewswire Inc.AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
 Showing the most relevant articles for your search:AMEX:AIM

Kürzlich von Ihnen besucht

TG
BAYN
Bayer
COIN
SOLUSD
Solana
NYSE
DIS
Walt Disney
CCOM
SILVER
SILVER
NASDAQ
GOOGL
Alphabet
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
TG
MBG
MercedesBenz
NASDAQ
QQQ
Invesco QQQ Trust Series 1
DBI
TDXP
Tec DAX
DBI
DAX
DAX
USOTC
BASFY
BASF (QX)
AMEX
XLV
Health Care Select Sector
PM
XAUUSD
Gold vs US Dollar
TG
DBK
Deutsche Bank
TG
DTE
Deutsche Telekom
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten